242 related articles for article (PubMed ID: 10986186)
1. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
Rosenfeld JA
West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
[No Abstract] [Full Text] [Related]
2. Raloxifene and risk of vertebral fracture in postmenopausal women.
Halbekath J; Becker-Brüser W; Wille H
JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
[No Abstract] [Full Text] [Related]
3. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene: recent information on skeletal and non-skeletal effects.
Gluck O; Maricic M
Curr Opin Rheumatol; 2002 Jul; 14(4):429-32. PubMed ID: 12118180
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
6. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.
Maricic M; Adachi JD; Sarkar S; Wu W; Wong M; Harper KD
Arch Intern Med; 2002 May; 162(10):1140-3. PubMed ID: 12020184
[TBL] [Abstract][Full Text] [Related]
7. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.
Johnell O; Kanis JA; Black DM; Balogh A; Poor G; Sarkar S; Zhou C; Pavo I
J Bone Miner Res; 2004 May; 19(5):764-72. PubMed ID: 15068500
[TBL] [Abstract][Full Text] [Related]
8. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
9. Another selective estrogen-receptor modulator for osteoporosis.
Becker C
N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
[No Abstract] [Full Text] [Related]
10. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
11. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of vertebral osteoporosis.
Lippuner K
Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
[TBL] [Abstract][Full Text] [Related]
14. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
Riggs BL; Melton LJ
J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
[No Abstract] [Full Text] [Related]
15. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
[TBL] [Abstract][Full Text] [Related]
16. Skeletal and nonskeletal effects of raloxifene.
Gluck O; Maricic M
Curr Osteoporos Rep; 2003 Dec; 1(3):123-8. PubMed ID: 16036075
[TBL] [Abstract][Full Text] [Related]
17. Reduction of vertebral fracture risk with raloxifene.
Bashore R
J Fam Pract; 1999 Nov; 48(11):911-2. PubMed ID: 10907630
[No Abstract] [Full Text] [Related]
18. [Treatment of postmenopausal osteoporosis with raloxifene].
Fedelesova V; Chylova K; Dzurik
Bratisl Lek Listy; 2000; 101(9):527-8. PubMed ID: 11187059
[TBL] [Abstract][Full Text] [Related]
19. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
20. Vertebral fractures: a hidden problem of osteoporosis.
Haczynski J; Jakimiuk A
Med Sci Monit; 2001; 7(5):1108-17. PubMed ID: 11535963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]